RE: Allogeneic off the shelf fast track designation29 Mar 2026 10:58
Exactly pumkin a update is long overdue.
I find it beyond strange that people are arguing against me asking for better investor relations and accountability of the management team. Vlad should publish a detailed roadmap for HEMO which he can be held against.
How long will tech transfer take? No idea
Are the patience still alive? No idea
What were results of detailed tests after P3 dosed? No idea
When will Estonia lead to a formal contract, is it still live? No idea
CBR/CDX... silence, despite recent funds raised from investors to progress these.
Vlad entire investor relations plan and business strategy boils down to "trust me bro". It's sad because I believe fundamentally hemo has some very interesting potentially fantastic science.
Why cant hemo start a R&D spotlight series for example? Its very cheap, all you need is a video camera and it would do wonders for investor relations keeping current investors engaged and enticing new ones.
Avacta did this and I suggested it here but instead of watching a few and thinking oh yeah thats a good idea, we should lobby vlad for something similar all yall did was cry about it and attack me.
I since left this board but kept a eye on from distance and multiple people like Bline and Micky come to the avacta board and start having a go at me again. Now im back here lol